1Neurosciences Graduate Program, Stanford University, Stanford, CA, USA 2Department of Neurosurgery, Stanford University School of Medicine, Palo Alto, CA, USA
OPEN PEER REVIEW
REVIEWER STATUS
Abstract
Neurons demand vast and vacillating supplies of energy. As the key contributors of this energy, as well as primary pools of calcium and signaling molecules, mitochondria must be where the neuron needs them, when the neuron needs them. The unique architecture and length of neurons, however, make them a complex system for mitochondria to navigate. To add to this difficulty, mitochondria are synthesized mainly in the soma, but must be transported as far as the distant terminals of the neuron. Similarly, damaged mitochondria—which can cause oxidative stress to the neuron—must fuse with healthy mitochondria to repair the damage, return all the way back to the soma for disposal, or be eliminated at the terminals. Increasing evidence suggests that the improper distribution of mitochondria in neurons can lead to neurodegenerative and neuropsychiatric disorders. Here, we will discuss the machinery and regulatory systems used to properly distribute mitochondria in neurons, and how this knowledge has been leveraged to better understand neurological dysfunction.
Corresponding author:
Xinnan Wang
Competing interests:
The author(s) declared that they have no competing interests.
Grant information:
This work was supported by the Alfred P. Sloan Foundation (Xinnan Wang), the Klingenstein Foundation (Xinnan Wang), the California Institute of Regenerative Medicine (Xinnan Wang), the National Institutes of Health (RO1NS089583) (Xinnan Wang), and the Graduate Research Fellowship Program of the National Science Foundation (Meredith M. Course).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
The transport of mitochondria is critical to a neuron’s health. Although frequently referred to as “the powerhouse of the cell”, mitochondria do much more than produce ATP. In addition to being the cell’s major energy provider, mitochondria are responsible for storing and buffering Ca2+, detoxifying ammonia, and producing some steroids1, heme compounds2, heat, and reactive oxygen species. They are vital to the metabolism of neurotransmitters glutamate and gamma-aminobutyric acid (GABA)3, and send signals for apoptosis, proliferation, and cell survival4. They even boast their own DNA and protein synthesis machinery as a vestige of their previous life as bacteria. It is thus unsurprising to learn that precise control of mitochondrial number, health, and distribution is especially critical to the neuron, which is a complex cell with high energy and regulatory demands.
Several features distinguish neurons from other cells. First, they have a long, thin axon—the longest axon in the human body can extend over one meter—and contain many areas of sub-specialization, like the pre-synapse, post-synapse, growth cones, and nodes of Ranvier5, each with different metabolic needs. Second, as the carriers of synaptic information, neurons have ever-changing energy and Ca2+ buffering demands, especially at their terminals. Finally, because neurons are post-mitotic and will stay with the organism for the duration of its life, they must be protected from excitotoxicity and kept in a state of homeostasis as long as possible. The appropriate allocation and sustenance of mitochondria are essential to fulfilling the many demands of the neuron, and keeping it in good health.
To meet the vacillating needs of neurons, about 30% to 40% of these spry organelles are in motion at any given time6–9. Properly distributing mitochondria throughout a neuron, however, is complicated by the fact that mitochondria are primarily produced in the soma, with most of their proteins encoded by nuclear DNA, but are needed as far away as the synaptic terminal. Static mitochondria pool at or near synapses, which may be important for rapid neuronal firing, while passing mitochondria may be recruited to support prolonged energy needs and repetitive neuronal firing10–12. Additionally, damaged mitochondria produce reactive oxygen species, which can be toxic to the cell, and these dysfunctional mitochondria must be repaired by fusing with new mitochondria transported from the soma, be returned to the soma for degradation in a process termed mitophagy, or be cleared through mitophagy in neurites in situ13. Whether providing a service to the neuron, or needing clearance to prevent damage to the neuron, mitochondria must travel long distances and know precisely where and when to stop. When their transport machinery breaks down or signals regulating this machinery cannot be relayed, the consequence can be injury to or even death of the neuron9,14–17. Here we will review the molecular mechanisms underlying mitochondrial transport in neurons, and what happens when they are disrupted.
Transport machinery
Much like a train, organelle transport requires a track, a motor, and a cargo. For mitochondria—the cargo—the overwhelming majority of their tracks are microtubules, which in mammalian neurons have their plus ends oriented toward the axon terminal, and their minus ends toward the soma (although this homogeny is not the case in dendrites)18–20. This uniform polarity makes neuronal axons an especially useful model for studying organelle transport. The motors used to transport mitochondria depend on the direction in which they need to travel. In general, mitochondria move in the anterograde direction (away from the soma) using a family of kinesin motors, and move in the retrograde direction (toward the cell body) using the dynein motor21. While kinesins and dynein are also used to carry other cargos, the motor adaptors that anchor the motor and cargo together are cargo-specific, allowing for the regulation of movement by particular cellular signals. In addition to microtubules, mitochondrial movement can be powered along actin filaments by myosin motors, a process that is required for short-range movement, and for opposing movement along the microtubules22–24.
Anterograde movement with the kinesin heavy chain complex
The best-characterized mitochondrial transport complex to date uses kinesin heavy chain (KHC, a member of the kinesin-1 family) as its motor, and Miro and milton as its motor adaptors. Miro stands for “mitochondrial Rho” and belongs to the atypical Rho (Ras homolog) family of GTPases (RhoT1/2 in mammals). Miro is anchored to the outer mitochondrial membrane (OMM) via its carboxy-terminus transmembrane domain. Miro binds to milton (trafficking protein, kinase-binding, or TRAK1/2 in mammals), which in turn binds to the carboxy-terminus of KHC25–27. Milton was identified in a Drosophila screen for blind flies and was named after the great poet and polemicist John Milton, who was also blind28. Together, Miro and milton facilitate anterograde mitochondrial movement along microtubules by connecting mitochondria to KHC (Figure 1a). When either Miro or milton is mutated in animal models, mitochondria are trapped in the soma and lose the ability to move out into the axons9,14–16,26,28.
Figure 1. Schematic representation of mitochondrial transport machinery.
(a) The primary motor/adaptor complex mediating anterograde mitochondrial transport along microtubules (purple), including kinesin heavy chain (KHC) (red), Miro (orange), and milton (blue). (b) The machinery mediating retrograde mitochondrial transport along microtubules (purple), including dynein (green), dynactin (gold), and a potential motor adaptor, Protein X (pink). Protein X could be the milton/Miro complex39. (c) Mitochondrial movement along actin filaments (olive), using a myosin motor (fuschia) and a potential motor adaptor, Protein X (yellow).
Miro and milton are not the only adaptors that can link mitochondria and KHC. Syntabulin can bind directly to the OMM and KHC, and disruption of syntabulin function has been shown to inhibit the anterograde transport of mitochondria in neurons29. Similarly, disrupting fasciculation and elongation protein zeta-1 (FEZ1), and RAN-binding protein 2 (RANBP2) also affects mitochondrial distribution because of their association with kinesins, possibly KIF3A and KIF5B/C, respectively30–34.
Mutations in KHC have been shown to reduce anterograde mitochondrial movement but do not eliminate it entirely, which suggests that other kinesin motors may also play a role in anterograde mitochondrial motility21. For example, kinesins from the Kinesin-3 family KIF1Bα and KLP6 may interact with KIF1 binding protein (KBP) to transport mitochondria35–38. KIF1B can transport mitochondria along microtubules in vitro, and mutations in Klp6 inhibits anterograde mitochondrial motility into neurites; however, the roles of these other kinesins await further clarification.
Retrograde movement with the dynein complex
Dynein is thought to act as the retrograde motor for microtubule-based mitochondrial movement, although far less is known about the mechanisms underlying its action. In contrast to the host of kinesins available for anterograde transport, there is only one identified dynein motor; however, dynein’s larger and more complex structure has made it difficult to study. Dynein has been shown to form a complex with dynactin, and this complex has been shown to also interact with milton/TRAK2 and with Miro39, which lends support to dynein’s role in mitochondrial transport (Figure 1b). Interestingly, dynein movement is also thought to depend on kinesin-1, as mutation in kinesin-1 reduces retrograde movement of mitochondria21.
Actin-based movement with myosin complexes
A small though not insignificant number of mitochondria are also transported along actin filaments22. This is more common in actin-enriched neuronal compartments, like growth cones, dendritic spines, and synaptic boutons. Myosins are actin-based motors, and the myosin Myo19 has been shown to anchor directly to the OMM, and regulate mitochondrial motility24, 40. Myosins V and VI have also been shown to play a role in mitochondrial motility by opposing microtubule-based mitochondrial transport23, although whether these myosin motors attach directly to mitochondria or require a motor adaptor remains unknown (Figure 1c). WAVE1 (WASP family verprolin homologous protein 1), which regulates actin polymerization, has been shown to be critical for mitochondrial transport in dendritic spines and filopodia—areas that are actin-rich—and therefore may be involved in the actin-based transport of mitochondria41.
Anchoring mitochondria
If 30% to 40% of mitochondria are in motion at any given time, then more than half of mitochondria are static. While understanding of how stationary pools of mitochondria are generated is still nascent, one protein, syntaphilin, stands out. Syntaphilin serves as a molecular brake, docking mitochondria by binding to both the mitochondrial surface and to the microtubule42. Both kinesin-1 and the dynein light chain component LC8 have been shown to regulate this mechanism43,44. Intriguingly, a recent study using optogenetics has shown that the mitochondrial dance between mobility and stabilization depends on the balance of forces between motors and anchors, rather than all-or-none switching45.
Regulation of the kinesin heavy chain/milton/Miro complex
Ca2+
The ability of mitochondria to temporarily stop where they are needed is just as important as their ability to move. When cytosolic Ca2+ concentration is elevated, Ca2+ binds to the EF hands of Miro and triggers a transient and instantaneous conformational change in the KHC/milton/Miro complex. This conformational change causes dissociation of either the whole complex from microtubules9, or KHC from mitochondria17, which arrests movement of mitochondria. When Ca2+ concentration is lowered, Ca2+ is removed from Miro, and mitochondria are reattached to microtubules by the complex and can start moving again. The sensitivity of mitochondrial movement to Ca2+ is likely a means by which mitochondria can be recruited to areas of high metabolic demand or low local ATP, like post-synaptic specializations and growth cones. During glutamate receptor activation, mitochondria are recruited where Ca2+ influx is increased, which confers neurons with resistance to excitotoxicity9,17. Interestingly, brain-derived neurotrophic factor (BDNF) has recently been shown to arrest mitochondrial motility via Ca2+ binding to Miro1 in cultured hippocampal neurons46.
Glucose
Glucose has recently been shown to influence mitochondrial motility via the KHC/milton/Miro complex. The small sugar UDP-GlcNAc is derived from glucose through the hexamine biosynthetic pathway. UDP-GlcNAc is affixed to milton by O-GlcNAc transferase (OGT), in a process called O-GlcNAcylation47. Extracellular glucose concentration or OGT activity can modulate mitochondrial motility through O-GlcNAcylation of milton. This mechanism links nutrient availability to mitochondrial distribution, which could be a mechanism by which neurons maintain a balanced metabolic state.
PINK1/Parkin
When mitochondria are severely damaged, they undergo mitophagy, a crucial cellular mechanism that eliminates depolarized mitochondria through autophagosomes and lysosomes. Damaged mitochondria must be stopped prior to the initiation of mitophagy. To accomplish this, mitochondrial depolarization activates PINK1 (PTEN-induced putative kinase 1)-mediated phosphorylation of Miro16,48, which subsequently triggers Parkin-dependent proteasomal degradation of Miro, thus releasing the mitochondria from its microtubule motors16,49. It is likely that stopping mitochondria in this manner is an early step in the quarantine of damaged mitochondria before degradation. In fact, this PINK1-mediated phosphorylation of Miro has been shown to protect dopaminergic neurons in vivo in Drosophila50. PINK1 and Parkin can also work in concert to remove damaged mitochondria through local mitophagy in distal axons, which would obviate the need for the mitochondria to be transported all the way back to the soma, and instead require the recruitment of autophagosomes to the damaged mitochondria13. How a cell chooses between transporting a mitochondrion back to the soma or using local mitophagy when it is damaged in the axon remains an outstanding question.
The dynamics of mitochondrial fission and fusion also plays a central role in PINK1/Parkin-mediated mitophagy. For example, mitofusin, a large GTPase that regulates mitochondrial fusion, is a target of the PINK1/Parkin pathway. Degradation of mitofusin prevents mitochondria from being able to fuse, and they instead fragment, a critical step prior to mitophagy51–55. An in-depth discussion of the role of mitochondrial dynamics in quality control merits its own review, and an excellent F1000 Faculty Review and two others are recommended in the References section56–58.
Other milton/Miro regulators
In humans, milton is encoded by two different genes: TRAK1 and TRAK2. It has been reported that TRAK1 binds to both kinesin-1 and dynein, while TRAK2 predominantly favors dynein39. In Drosophila, milton has several splicing variants, one of which (milton-C) does not bind to KHC26. These varying forms of milton may play an important role in regulating the KHC/milton/Miro complex.
Another regulator that merits mentioning is HUMMR (hypoxia up-regulated mitochondrial movement regulator), whose expression is induced by hypoxic conditions. HUMMR has been shown to interact with the KHC/milton/Miro complex, and increases the ratio of anterograde to retrograde movement of mitochondria59. Similarly, a family of proteins encoded by an array of armadillo (Arm) repeat-containing genes has been shown to bind to milton/Miro and regulate mitochondrial motility60.
It is worthwhile to note that mitochondrial fission and fusion also affect mitochondrial motility. The same mitofusin mentioned previously also binds to milton/Miro, and knockdown of mitofusin 2 has been shown to inhibit mitochondrial motility61. Additionally, transient fusion has been shown to promote mitochondrial movement62.
Other regulators
The list of possible mitochondrial transport regulators burgeons daily, although thorough mechanisms remain scarce. For example, nerve growth factor can cause accumulation of mitochondria to its site of application63,64. Another growth factor, lysophosphatidic acid, can inhibit mitochondrial movement65. Intracellular ATP levels regulate mitochondrial motility, which decreases when close to synapses, and local production of ADP can recruit more mitochondria to areas requiring more ATP66,67. Increased cAMP can increase mitochondrial motility68. Pharmacological activation of AMP-activated protein kinase (AMPK) can promote anterograde movement of mitochondria for the formation of axon branches69. Activation of the serotonin receptor increases mitochondrial movement via the AKT-GSK3β (Akt-glycogen synthase kinase 3β) pathway6, and conversely, dopamine and activation of the dopamine receptor D2 can inhibit mitochondrial movement via the same AKT-GSK3β pathway70,71. One recent study shows that GSK-3β directly regulates dynein72, while another study shows that it promotes anterograde movement68. This list of molecules likely skims the surface of all the signals and sensors involved in mitochondrial motility, which are yet to be uncovered.
Implications for neurological disorders
Because mitochondria are critical for energy production, calcium buffering, and cell survival pathways, it is not surprising to learn that impaired mitochondrial movement has been linked to neuronal dysfunction and neurological disorders73–75. The long distance travelled by mitochondria in neurons, as compared to in other cells, may account for the fact that neurons are more vulnerable to impairments in mitochondrial transport. Altered mitochondrial motility may provide an early indication of neuronal pathology prior to cell death, either because motility is directly affected or because it is altered as a consequence of other mitochondrial malfunctions.
Neurodegenerative diseases
Aging itself has been shown to decrease neuronal mitochondrial motility in mice, and several age-dependent neurodegenerative diseases have been linked to mitochondrial motility defects76. Mutations in the previously mentioned PINK1 and Parkin are both causes of familial Parkinson’s disease (PD)77,78. In individuals lacking either functional PINK1 or Parkin, a failure to isolate, stop, and remove the damaged mitochondria may contribute to neuronal cell death. Unpublished work using patients’ samples from our laboratory also suggests that neurodegeneration in non-PINK1/Parkin-related PD cases may arise in a similar manner, and that stopping damaged mitochondrial motility is neuroprotective. This finding highlights the broader implications of mitochondrial motility in neuronal health and pathology.
The pathological forms of amyloid beta and tau, the chief markers of Alzheimer’s disease (AD), have both been shown to inhibit mitochondrial motility in several AD models79–83. Superoxide dismutase 1, soluble (SOD1), fused in sarcoma (FUS), C9orf72, and TAR DNA-binding protein 43 (TDP-43) mutations, which cause familial amyotrophic lateral sclerosis (also called Lou Gehrig’s disease), have also been shown to impair mitochondrial transport in mice, flies, and cultured neuronal models84–91. Mutant huntingtin protein, with the polyglutamine expansions characteristic of Huntington’s disease etiology, can act to “jam traffic” by mechanical obstruction, and may also bind to milton or even to the mitochondria itself to disrupt mitochondrial motility92–94. Mutations in mitofusin 2 causing Charcot-Marie-Tooth disease alter mitochondria movement95, and finally, mitochondrial motility defects have also been observed in models of hereditary spastic paraplegia, a disease characterized by axonal degeneration96,97.
Neuropsychiatric disorders
A few psychiatric disorders have also been linked to mitochondrial motility defects. Mutations in disrupted in schizophrenia 1 (DISC1) may contribute to both schizophrenia and some forms of depression98. DISC1 complexes with TRAK1/milton and Miro1 to modulate anterograde transport of mitochondria99,100, and its interactors NDE1 and GSK3β have recently been shown to associate with TRAK1/milton and similarly play a role in mitochondrial motility68. DISC1 also interacts with the previously mentioned FEZ1101, which binds to kinesins25,28. Among several causes, depression can be attributed to a loss of serotonin102. Interestingly, the application of serotonin to cultured hippocampal neurons has been shown to increase mitochondrial motility6.
Closing remarks
The proper transport of mitochondria in neurons is critical to the homeostasis of the cell. Many questions in this field, however, remain to be answered. On a basic level of investigation, a more thorough understanding of the machinery—like the dynein motor, myosin motors, and the signals and adaptors that regulate this complex system—is still desperately needed.
A significant higher-level question is: how does the cell decide what to do with a damaged mitochondrion in the distal segment of an axon? The cell has several options: return the mitochondria to the soma for lysosomal degradation, which requires long-distance retrograde transport; degrade the mitochondrion via local mitophagy, which requires recruitment of autophagosomes to mitochondria and fusion of autophagosomes with lysosomes in the axon; or send a healthy mitochondrion from the soma via anterograde transport to repair the damage by fusing with the unhealthy mitochondrion. Could this decision be made on the basis of the nature or severity of the damage to the mitochondrion? Does this decision take into account the relative energy expended? What are the signals and molecules that execute this decision? These actions must also be influenced by the local metabolic state, de novo protein synthesis, and neuronal activity in extremities far from the cell body.
It is also crucial to explore the translational implications of these findings. What of this knowledge can be leveraged for therapeutic benefit? Perhaps mitochondrial motility could be used as a novel phenotypic readout to screen for more effective treatments for neurological disorders, as well as a way to diagnose the disease and monitor its progression. A more comprehensive understanding of the molecular mechanisms underlying mitochondrial transport will prove invaluable as it provides novel targets, like the KHC/milton/Miro complex, for diagnostic innovation and therapeutic intervention.
Most knowledge of mitochondrial movement in neurons has been uncovered using cultured rodent neurons. The application of emerging in vivo models will shed light on the physiological significance of the regulation of mitochondrial motility76,103–107. Therefore, imaging mitochondria in living animals, especially during development and aging, as well as under disease conditions, will be an important step for the field.
Finally, given the inseparable relationship between neuronal function and metabolism, and mitochondrial motility and distribution, their underlying regulatory mechanisms must be interwoven. How do action potentials, neuronal signaling molecules like dopamine and serotonin, or metabolites like glucose, fatty acids, and amino acids influence mitochondrial motility and distribution? And how do mitochondrial motility and function reciprocally control neuronal homeostasis? Answers to these questions will reveal how neurons respond to changes in their activities and environments by regulating this cellular linchpin.
Competing interests
The author(s) declared that they have no competing interests.
Grant information
This work was supported by the Alfred P. Sloan Foundation (Xinnan Wang), the Klingenstein Foundation (Xinnan Wang), the California Institute of Regenerative Medicine (Xinnan Wang), the National Institutes of Health (RO1NS089583) (Xinnan Wang), and the Graduate Research Fellowship Program of the National Science Foundation (Meredith M. Course).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Faculty Opinions recommended
References
1.
Rossier MF:
T channels and steroid biosynthesis: in search of a link with mitochondria.
Cell Calcium.
2006; 40(2): 155–64. PubMed Abstract
| Publisher Full Text
2.
Oh-hama T:
Evolutionary consideration on 5-aminolevulinate synthase in nature.
Orig Life Evol Biosph.
1997; 27(4): 405–12. PubMed Abstract
| Publisher Full Text
3.
Kugler P, Baier G:
Mitochondrial enzymes related to glutamate and GABA metabolism in the hippocampus of young and aged rats: a quantitative histochemical study.
Neurochem Res.
1992; 17(2): 179–85. PubMed Abstract
| Publisher Full Text
4.
McBride HM, Neuspiel M, Wasiak S:
Mitochondria: more than just a powerhouse.
Curr Biol.
2006; 16(14): R551–60. PubMed Abstract
| Publisher Full Text
14.
Guo X, Macleod GT, Wellington A, et al.:
The GTPase dMiro is required for axonal transport of mitochondria to Drosophila synapses.
Neuron.
2005; 47(3): 379–93. PubMed Abstract
| Publisher Full Text
18.
Baas PW, Deitch JS, Black MM, et al.:
Polarity orientation of microtubules in hippocampal neurons: uniformity in the axon and nonuniformity in the dendrite.
Proc Natl Acad Sci U S A.
1988; 85(21): 8335–9. PubMed Abstract
| Publisher Full Text
| Free Full Text
19.
Baas PW, Black MM, Banker GA:
Changes in microtubule polarity orientation during the development of hippocampal neurons in culture.
J Cell Biol.
1989; 109(6 Pt 1): 3085–94. PubMed Abstract
| Publisher Full Text
| Free Full Text
20.
Heidemann SR, Landers JM, Hamborg MA:
Polarity orientation of axonal microtubules.
J Cell Biol.
1981; 91(3 Pt 1): 661–5. PubMed Abstract
| Free Full Text
22.
Morris RL, Hollenbeck PJ:
Axonal transport of mitochondria along microtubules and F-actin in living vertebrate neurons.
J Cell Biol.
1995; 131(5): 1315–26. PubMed Abstract
| Publisher Full Text
| Free Full Text
23.
Pathak D, Sepp KJ, Hollenbeck PJ:
Evidence that myosin activity opposes microtubule-based axonal transport of mitochondria.
J Neurosci.
2010; 30(26): 8984–92. PubMed Abstract
| Publisher Full Text
| Free Full Text
25.
Fransson S, Ruusala A, Aspenström P:
The atypical Rho GTPases Miro-1 and Miro-2 have essential roles in mitochondrial trafficking.
Biochem Biophys Res Commun.
2006; 344(2): 500–10. PubMed Abstract
| Publisher Full Text
29.
Cai Q, Gerwin C, Sheng ZH:
Syntabulin-mediated anterograde transport of mitochondria along neuronal processes.
J Cell Biol.
2005; 170(6): 959–69. PubMed Abstract
| Publisher Full Text
| Free Full Text
30.
Suzuki T, Okada Y, Semba S, et al.:
Identification of FEZ1 as a protein that interacts with JC virus agnoprotein and microtubules: role of agnoprotein-induced dissociation of FEZ1 from microtubules in viral propagation.
J Biol Chem.
2005; 280(26): 24948–56. PubMed Abstract
| Publisher Full Text
31.
Patil H, Cho KI, Lee J, et al.:
Kinesin-1 and mitochondrial motility control by discrimination of structurally equivalent but distinct subdomains in Ran-GTP-binding domains of Ran-binding protein 2.
Open Biol.
2013; 3(3): 120183. PubMed Abstract
| Publisher Full Text
| Free Full Text
32.
Cho KI, Cai Y, Yi H, et al.:
Association of the kinesin-binding domain of RanBP2 to KIF5B and KIF5C determines mitochondria localization and function.
Traffic.
2007; 8(12): 1722–35. PubMed Abstract
| Publisher Full Text
33.
Fujita T, Maturana AD, Ikuta J, et al.:
Axonal guidance protein FEZ1 associates with tubulin and kinesin motor protein to transport mitochondria in neurites of NGF-stimulated PC12 cells.
Biochem Biophys Res Commun.
2007; 361(3): 605–10. PubMed Abstract
| Publisher Full Text
34.
Ikuta J, Maturana A, Fujita T, et al.:
Fasciculation and elongation protein zeta-1 (FEZ1) participates in the polarization of hippocampal neuron by controlling the mitochondrial motility.
Biochem Biophys Res Commun.
2007; 353(1): 127–32. PubMed Abstract
| Publisher Full Text
35.
Nangaku M, Sato-Yoshitake R, Okada Y, et al.:
KIF1B, a novel microtubule plus end-directed monomeric motor protein for transport of mitochondria.
Cell.
1994; 79(7): 1209–20. PubMed Abstract
| Publisher Full Text
36.
Tanaka K, Sugiura Y, Ichishita R, et al.:
KLP6: a newly identified kinesin that regulates the morphology and transport of mitochondria in neuronal cells.
J Cell Sci.
2011; 124(pt 4): 2457–65. PubMed Abstract
| Publisher Full Text
37.
Wozniak MJ, Melzer M, Dorner C, et al.:
The novel protein KBP regulates mitochondria localization by interaction with a kinesin-like protein.
BMC Cell Biol.
2005; 6: 35. PubMed Abstract
| Publisher Full Text
| Free Full Text
38.
Lyons DA, Naylor SG, Mercurio S, et al.:
KBP is essential for axonal structure, outgrowth and maintenance in zebrafish, providing insight into the cellular basis of Goldberg-Shprintzen syndrome.
Development.
2008; 135(3): 599–608. PubMed Abstract
| Publisher Full Text
43.
Chen YM, Gerwin C, Sheng ZH:
Dynein light chain LC8 regulates syntaphilin-mediated mitochondrial docking in axons.
J Neurosci.
2009; 29(30): 9429–38. PubMed Abstract
| Publisher Full Text
44.
Chen Y, Sheng ZH:
Kinesin-1-syntaphilin coupling mediates activity-dependent regulation of axonal mitochondrial transport.
J Cell Biol.
2013; 202(2): 351–64. PubMed Abstract
| Publisher Full Text
| Free Full Text
47.
Pekkurnaz G, Trinidad JC, Wang X, et al.:
Glucose regulates mitochondrial motility via Milton modification by O-GlcNAc transferase.
Cell.
2014; 158(1): 54–68. PubMed Abstract
| Publisher Full Text
| Free Full Text
50.
Tsai PI, Course MM, Lovas JR, et al.:
PINK1-mediated phosphorylation of Miro inhibits synaptic growth and protects dopaminergic neurons in Drosophila.
Sci Rep.
2014; 4: 6962. PubMed Abstract
| Publisher Full Text
| Free Full Text
53.
Poole AC, Thomas RE, Yu S, et al.:
The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway.
PLoS One.
2010; 5(4): e10054. PubMed Abstract
| Publisher Full Text
| Free Full Text
55.
Ziviani E, Tao RN, Whitworth AJ:
Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin.
Proc Natl Acad Sci U S A.
2010; 107(11): 5018–23. PubMed Abstract
| Publisher Full Text
| Free Full Text
59.
Li Y, Lim S, Hoffman D, et al.:
HUMMR, a hypoxia- and HIF-1alpha-inducible protein, alters mitochondrial distribution and transport.
J Cell Biol.
2009; 185(6): 1065–81. PubMed Abstract
| Publisher Full Text
| Free Full Text
60.
López-Doménech G, Serrat R, Mirra S, et al.:
The Eutherian Armcx genes regulate mitochondrial trafficking in neurons and interact with Miro and Trak2.
Nat Commun.
2012; 3: 814. PubMed Abstract
| Publisher Full Text
61.
Misko A, Jiang S, Wegorzewska I, et al.:
Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex.
J Neurosci.
2010; 30(12): 4232–40. PubMed Abstract
| Publisher Full Text
| Free Full Text
63.
Chada SR, Hollenbeck PJ:
Mitochondrial movement and positioning in axons: the role of growth factor signaling.
J Exp Biol.
2003; 206(Pt 12): 1985–92. PubMed Abstract
| Publisher Full Text
65.
Minin AA, Kulik AV, Gyoeva FK, et al.:
Regulation of mitochondria distribution by RhoA and formins.
J Cell Sci.
2006; 119(Pt 4): 659–70. PubMed Abstract
| Publisher Full Text
67.
Mironov SL:
Complexity of mitochondrial dynamics in neurons and its control by ADP produced during synaptic activity.
Int J Biochem Cell Biol.
2009; 41(10): 2005–14. PubMed Abstract
| Publisher Full Text
68.
Ogawa F, Murphy LC, Malavasi EL, et al.:
NDE1 and GSK3β Associate with TRAK1 and Regulate Axonal Mitochondrial Motility: Identification of Cyclic AMP as a Novel Modulator of Axonal Mitochondrial Trafficking.
ACS Chem Neurosci.
2016; 7(5): 553–64. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
73.
de Vos KJ, Grierson AJ, Ackerley S, et al.:
Role of axonal transport in neurodegenerative diseases.
Annu Rev Neurosci.
2008; 31: 151–73. PubMed Abstract
| Publisher Full Text
75.
Deheshi S, Pasqualotto BA, Rintoul GL:
Mitochondrial trafficking in neuropsychiatric diseases.
Neurobiol Dis.
2013; 51: 66–71. PubMed Abstract
| Publisher Full Text
76.
Gilley J, Seereeram A, Ando K, et al.:
Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a "P301L" tau knockin mouse.
Neurobiol Aging.
2012; 33(3): 621.e1–621.e15. PubMed Abstract
| Publisher Full Text
78.
Kitada T, Asakawa S, Hattori N, et al.:
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.
Nature.
1998; 392(6676): 605–8. PubMed Abstract
| Publisher Full Text
81.
Rui Y, Tiwari P, Xie Z, et al.:
Acute impairment of mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons.
J Neurosci.
2006; 26(41): 10480–7. PubMed Abstract
| Publisher Full Text
83.
Calkins MJ, Reddy PH:
Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons.
Biochim Biophys Acta.
2011; 1812(4): 507–13. PubMed Abstract
| Publisher Full Text
| Free Full Text
84.
Sasaki S, Iwata M:
Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis.
Neurology.
1996; 47(2): 535–40. PubMed Abstract
| Publisher Full Text
85.
De Vos KJ, Chapman AL, Tennant ME, et al.:
Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content.
Hum Mol Genet.
2007; 16(22): 2720–8. PubMed Abstract
| Publisher Full Text
| Free Full Text
89.
Shi P, Ström AL, Gal J, et al.:
Effects of ALS-related SOD1 mutants on dynein- and KIF5-mediated retrograde and anterograde axonal transport.
Biochim Biophys Acta.
2010; 1802(9): 707–16. PubMed Abstract
| Publisher Full Text
| Free Full Text
92.
Trushina E, Dyer RB, Badger JD 2nd, et al.:
Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro.
Mol Cell Biol.
2004; 24(18): 8195–209. PubMed Abstract
| Publisher Full Text
| Free Full Text
93.
Chang DT, Rintoul GL, Pandipati S, et al.:
Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons.
Neurobiol Dis.
2006; 22(2): 388–400. PubMed Abstract
| Publisher Full Text
95.
Baloh RH, Schmidt RE, Pestronk A, et al.:
Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations.
J Neurosci.
2007; 27(2): 422–30. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
96.
Ferreirinha F, Quattrini A, Pirozzi M, et al.:
Axonal degeneration in paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport.
J Clin Invest.
2004; 113(2): 231–42. PubMed Abstract
| Publisher Full Text
| Free Full Text
97.
Kasher PR, De Vos KJ, Wharton SB, et al.:
Direct evidence for axonal transport defects in a novel mouse model of mutant spastin-induced hereditary spastic paraplegia (HSP) and human HSP patients.
J Neurochem.
2009; 110(1): 34–44. PubMed Abstract
| Publisher Full Text
98.
Millar JK, Wilson-Annan JC, Anderson S, et al.:
Disruption of two novel genes by a translocation co-segregating with schizophrenia.
Hum Mol Genet.
2000; 9(9): 1415–23. PubMed Abstract
| Publisher Full Text
99.
Atkin TA, MacAskill AF, Brandon NJ, et al.:
Disrupted in Schizophrenia-1 regulates intracellular trafficking of mitochondria in neurons.
Mol Psychiatry.
2011; 16(2): 122–4, 121. PubMed Abstract
| Publisher Full Text
101.
Miyoshi K, Honda A, Baba K, et al.:
Disrupted-In-Schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth.
Mol Psychiatry.
2003; 8(7): 685–94. PubMed Abstract
| Publisher Full Text
104.
Misgeld T, Kerschensteiner M, Bareyre FM, et al.:
Imaging axonal transport of mitochondria in vivo.
Nat Methods.
2007; 4(7): 559–61. PubMed Abstract
| Publisher Full Text
107.
Plucinska G, Paquet D, Hruscha A, et al.:
In vivo imaging of disease-related mitochondrial dynamics in a vertebrate model system.
J Neurosci.
2012; 32(46): 16203–12. PubMed Abstract
| Publisher Full Text
1
Neurosciences Graduate Program, Stanford University, Stanford, CA, USA 2
Department of Neurosurgery, Stanford University School of Medicine, Palo Alto, CA, USA
This work was supported by the Alfred P. Sloan Foundation (Xinnan Wang), the Klingenstein Foundation (Xinnan Wang), the California Institute of Regenerative Medicine (Xinnan Wang), the National Institutes of Health (RO1NS089583) (Xinnan Wang), and the Graduate Research Fellowship Program of the National Science Foundation (Meredith M. Course).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Course MM and Wang X. Transporting mitochondria in neurons [version 1; peer review: 2 approved] F1000Research 2016, 5(F1000 Faculty Rev):1735 (https://doi.org/10.12688/f1000research.7864.1)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.
Share
Open Peer Review
Current Reviewer Status:
?
Key to Reviewer Statuses
VIEWHIDE
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
I confirm that I have read this submission and believe that I have an
... Continue reading
Competing Interests: No competing interests were disclosed.
Faculty Reviews are commissioned and written by members of the prestigious Faculty Opinions Faculty, and are edited as a service to our readers. In order to make these reviews as comprehensive and accessible as possible, we seek the reviewers’ input before publication. The reviewers’ names and any additional comments they may have are published alongside the review, as is usual on F1000Research.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
I confirm that I have read this submission and believe that I have an
... Continue reading
Competing Interests: No competing interests were disclosed.
Faculty Reviews are commissioned and written by members of the prestigious Faculty Opinions Faculty, and are edited as a service to our readers. In order to make these reviews as comprehensive and accessible as possible, we seek the reviewers’ input before publication. The reviewers’ names and any additional comments they may have are published alongside the review, as is usual on F1000Research.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations -
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Adjust parameters to alter display
View on desktop for interactive features
Includes Interactive Elements
View on desktop for interactive features
Competing Interests Policy
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Examples of 'Non-Financial Competing Interests'
Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.
You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.
You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).
You work at the same institute as any of the authors.
You hope/expect to benefit (e.g. favour or employment) as a result of your submission.
You are an Editor for the journal in which the article is published.
Examples of 'Financial Competing Interests'
You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.
You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.
You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.
Stay Updated
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Comments on this article Comments (0)